Franklin Resources
EGRX

Franklin Resources’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Franklin Resources’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-6,174
Closed -$275K – 2431
2022
Q2 		$275K Sell
6,174
-2,422
-28% -$111K ﹤0.01% 1906
2022
Q1 		$425K Hold
8,596
– – ﹤0.01% 1893
2021
Q4 		$438K Buy
8,596
+100
+1% +$5.18K ﹤0.01% 1956
2021
Q3 		$473K Buy
+8,496
New +$418K ﹤0.01% 1899

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $113B AUM 36.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Franklin Resources's EGRX Position: Q3 2022 in Review

Franklin Resources sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2022, closing a stake of 6,174 shares — an estimated $275K sold.

Franklin Resources first reported a position in EGRX in Q3 2021 and held it in 4 quarters. The position peaked at $473K in Q3 2021. 153 funds tracked by Wall St. Rank hold EGRX as of Q3 2022.

  • Franklin Resources reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2022 after selling out during the quarter.
  • Franklin Resources sold 6,174 Eagle Pharmaceuticals, Inc. shares in Q3 2022, an estimated $275K.
  • Franklin Resources first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2021 and held it in 4 quarters.
  • Franklin Resources's Eagle Pharmaceuticals, Inc. position peaked at $473K in Q3 2021.
  • 153 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2022.

Based on Franklin Resources's 13F filing for Q3 2022, filed 14 Nov 2022.